As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Sector: Services-Commercial Physical & Biological Research
Industry: Medical - Diagnostics & Research
Past the 1:250 Nasdaq cap, ineligible for a bid-price compliance period
